As Edwards secures another win against its rival, LSIPR talks to Siddharth Kusumakar—partner at Powell Gilbert and counsel for the winning party. Already registered? If you don't have a login or your ...

22 October 2025 Just weeks into his tenure, USPTO director John Squires is blitzing US patent policy by taking control of how and when patent challenges can be brought, with proposed rules that could ...

28 November 2025 With EU trilogues deadlocked over the package, the future of drug exclusivities and access-linked obligations hangs in the balance. Jackie Mulryne and Paul Ranson of Morgan Lewis ...

Biopharma company and two others have taken action against numerous defendants over proposed generic versions of Livmarli, Mirum’s core revenue driver. If you don't have a login or your access has ...

Speakers from Greenberg Traurig, Verdiva Bio, Halozyme, and Metsera discuss the implications of the USPTO’s 2024 §112 guidelines on life sciences patents. If you don't have a login or your access has ...

Global law firm and Wall Street institution to join forces, forming one of the world’s five largest law firms by revenue and significantly expanding global and US market reach. If you don't have a ...

Dirk Buehler, Maiwald, discusses how the “try and see” standard is applied before the EPO and its relevance in pharma and biotech cases. If you don't have a login or your access has expired, you will ...

Amanda Simons, J A Kemp, explains how clinical research affects patentability in Europe and how clinical data can be used to strengthen protection. If you don't have a login or your access has expired ...

WATCH: Behind the scenes of big ticket litigation — lessons from the courts ...

The firm’s new hire is known for advising Boston’s biotech, pharmaceutical and chemical companies on patent strategies and ...

The proponents of a petition denied by the Supreme Court said it addressed a conflict that was significant “not just for the ...

Companies that integrate data rights into their IP strategy with a holistic approach will lead in innovation while minimising ...